Blood clot risk prompts suspension of sales of Iclusig

Ariad's Iclusig, or ponatinib, has been pulled from the market less than a year after it was approved for the treatment of chronic myeloid leukemia due to the risk of blood clots, according to the FDA. The agency and Ariad will work to identify patients who can be helped by the drug, and the withdrawal is not considered permanent.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC